Zhang Xiaojie, Khurana Arushi, Hirani Samina, Kidd Jason, Paul Asit
Department of Hematology and Oncology, University of California San Diego, San Diego, USA.
Division of Hematology, Mayo Clinic, Rochester, USA.
Cureus. 2023 Mar 30;15(3):e36928. doi: 10.7759/cureus.36928. eCollection 2023 Mar.
Paraneoplastic glomerulonephropathy (PGN) is a rare paraneoplastic syndrome that is associated with a variety of malignancies. Patients with renal cell carcinomas (RCCs) often develop paraneoplastic syndromes including PGN. To date, objective diagnostic criteria of PGN are not defined. As a result, the true occurrences are unknown. Many RCC patients develop renal insufficiency in the course of their disease, and diagnosis of PGN in this population is challenging and often delayed, which may lead to significant morbidity and mortality. Here, we provide a descriptive analysis of the clinical presentation, treatment, and outcomes of 35 published patient cases of PGN associated with RCCs over the past four decades in PubMed-indexed journals. Most patients with PGN were male (77%), over 60 years of age (60%), and diagnosed with PGN prior to or concurrent with their diagnosis of RCC (20% prior, 71% concurrent). Membranous nephropathy (34%) was the most common pathologic subtype. Among the patients with localized RCCs, 16 (67%) of 24 patients had improvement in PGN compared to 4 (36%) of 11 patients with metastatic RCCs. All 24 patients with localized RCCs underwent nephrectomy, but patients who were treated with nephrectomy with immunosuppression (7/9, 78%) had a better outcome than patients who were treated with nephrectomy alone (9/15, 60%). Among the patients with metastatic RCCs, patients who were treated with systemic therapy along with immunosuppression (4/5, 80%) had a better outcome than those who were treated with systemic therapy, nephrectomy, or immunosuppression alone (1/6, 17%). Our analysis demonstrates the importance of cancer-specific therapy; nephrectomy in localized disease and systemic therapy in metastatic disease, along with immunosuppression, was the effective management of PGN. Immunosuppression alone is not adequate in most patients. This is distinct from other glomerulonephropathy and warrants further study.
副肿瘤性肾小球病(PGN)是一种罕见的副肿瘤综合征,与多种恶性肿瘤相关。肾细胞癌(RCC)患者常出现包括PGN在内的副肿瘤综合征。迄今为止,PGN尚无客观的诊断标准。因此,其实际发病率尚不清楚。许多RCC患者在疾病过程中会出现肾功能不全,在这一人群中诊断PGN具有挑战性且常常延迟,这可能导致显著的发病率和死亡率。在此,我们对过去四十年来在PubMed索引期刊上发表的35例与RCC相关的PGN患者病例的临床表现、治疗及预后进行了描述性分析。大多数PGN患者为男性(77%),年龄超过60岁(60%),且在诊断RCC之前或同时被诊断为PGN(20%在之前,71%在同时)。膜性肾病(34%)是最常见的病理亚型。在局限性RCC患者中,24例患者中有16例(67%)的PGN有所改善,而转移性RCC患者中的11例患者中有4例(36%)有所改善。所有24例局限性RCC患者均接受了肾切除术,但接受肾切除术加免疫抑制治疗的患者(7/9,78%)比单纯接受肾切除术的患者(9/15,60%)预后更好。在转移性RCC患者中,接受全身治疗加免疫抑制治疗的患者(4/5,80%)比单纯接受全身治疗、肾切除术或免疫抑制治疗的患者(1/6,17%)预后更好。我们的分析表明了癌症特异性治疗的重要性;局限性疾病行肾切除术,转移性疾病行全身治疗,同时加用免疫抑制,是PGN的有效治疗方法。大多数患者仅用免疫抑制是不够的。这与其他肾小球病不同,值得进一步研究。